Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

Katerina Grafanaki; Ioannis Grammatikakis; Arin Ghosh; Vishaka Gopalan; Gulden Olgun; Huaitian Liu; George C Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos; Sridhar Hannenhalli; Glenn Merlino; Kerrie Marie; Chi-Ping Day

doi:10.1016/j.pharmthera.2023.108466

Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

Katerina Grafanaki
, Ioannis Grammatikakis
, Arin Ghosh
, Vishaka Gopalan
, Gulden Olgun
, Huaitian Liu
, George C Kyriakopoulos
, Ilias Skeparnias
, Sophia Georgiou
, Constantinos Stathopoulos
, Sridhar Hannenhalli
, Glenn Merlino
, Kerrie Marie
, Chi-Ping Day

Division of Molecular & Cellular Function (L5)

Research output: Contribution to journal › Review article › peer-review

Abstract

Melanoma, the cancer of the melanocyte, is the deadliest form of skin cancer with an aggressive nature, propensity to metastasize and tendency to resist therapeutic intervention. Studies have identified that the re-emergence of developmental pathways in melanoma contributes to melanoma onset, plasticity, and therapeutic response. Notably, it is well known that noncoding RNAs play a critical role in the development and stress response of tissues. In this review, we focus on the noncoding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and other small RNAs, for their functions in developmental mechanisms and plasticity, which drive onset, progression, therapeutic response and resistance in melanoma. Going forward, elucidation of noncoding RNA-mediated mechanisms may provide insights that accelerate development of novel melanoma therapies.

Original language	English
Pages (from-to)	108466
Journal	Pharmacology & therapeutics
Volume	248
Early online date	8 Jun 2023
DOIs	https://doi.org/10.1016/j.pharmthera.2023.108466
Publication status	Published - 1 Aug 2023

Keywords

Humans
RNA, Untranslated/genetics
MicroRNAs/genetics
Melanoma/drug therapy
RNA, Long Noncoding/genetics
RNA, Circular

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pharmthera.2023.108466

https://europepmc.org/articles/PMC10527631

Cite this

Grafanaki, K., Grammatikakis, I., Ghosh, A., Gopalan, V., Olgun, G., Liu, H., Kyriakopoulos, G. C., Skeparnias, I., Georgiou, S., Stathopoulos, C., Hannenhalli, S., Merlino, G., Marie, K., & Day, C.-P. (2023). Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response. Pharmacology & therapeutics, 248, 108466. https://doi.org/10.1016/j.pharmthera.2023.108466

@article{04d6b139908b4b7ab85a721b62822f23,

title = "Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response",

abstract = "Melanoma, the cancer of the melanocyte, is the deadliest form of skin cancer with an aggressive nature, propensity to metastasize and tendency to resist therapeutic intervention. Studies have identified that the re-emergence of developmental pathways in melanoma contributes to melanoma onset, plasticity, and therapeutic response. Notably, it is well known that noncoding RNAs play a critical role in the development and stress response of tissues. In this review, we focus on the noncoding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and other small RNAs, for their functions in developmental mechanisms and plasticity, which drive onset, progression, therapeutic response and resistance in melanoma. Going forward, elucidation of noncoding RNA-mediated mechanisms may provide insights that accelerate development of novel melanoma therapies.",

keywords = "Humans, RNA, Untranslated/genetics, MicroRNAs/genetics, Melanoma/drug therapy, RNA, Long Noncoding/genetics, RNA, Circular",

author = "Katerina Grafanaki and Ioannis Grammatikakis and Arin Ghosh and Vishaka Gopalan and Gulden Olgun and Huaitian Liu and Kyriakopoulos, \{George C\} and Ilias Skeparnias and Sophia Georgiou and Constantinos Stathopoulos and Sridhar Hannenhalli and Glenn Merlino and Kerrie Marie and Chi-Ping Day",

note = "Copyright {\textcopyright} 2023. Published by Elsevier Inc.",

year = "2023",

month = aug,

day = "1",

doi = "10.1016/j.pharmthera.2023.108466",

language = "English",

volume = "248",

pages = "108466",

journal = "Pharmacology \& therapeutics",

issn = "0163-7258",

publisher = "Elsevier BV",

}

Grafanaki, K, Grammatikakis, I, Ghosh, A, Gopalan, V, Olgun, G, Liu, H, Kyriakopoulos, GC, Skeparnias, I, Georgiou, S, Stathopoulos, C, Hannenhalli, S, Merlino, G, Marie, K & Day, C-P 2023, 'Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response', Pharmacology & therapeutics, vol. 248, pp. 108466. https://doi.org/10.1016/j.pharmthera.2023.108466

TY - JOUR

T1 - Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

AU - Grafanaki, Katerina

AU - Grammatikakis, Ioannis

AU - Ghosh, Arin

AU - Gopalan, Vishaka

AU - Olgun, Gulden

AU - Liu, Huaitian

AU - Kyriakopoulos, George C

AU - Skeparnias, Ilias

AU - Georgiou, Sophia

AU - Stathopoulos, Constantinos

AU - Hannenhalli, Sridhar

AU - Merlino, Glenn

AU - Marie, Kerrie

AU - Day, Chi-Ping

PY - 2023/8/1

Y1 - 2023/8/1

N2 - Melanoma, the cancer of the melanocyte, is the deadliest form of skin cancer with an aggressive nature, propensity to metastasize and tendency to resist therapeutic intervention. Studies have identified that the re-emergence of developmental pathways in melanoma contributes to melanoma onset, plasticity, and therapeutic response. Notably, it is well known that noncoding RNAs play a critical role in the development and stress response of tissues. In this review, we focus on the noncoding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and other small RNAs, for their functions in developmental mechanisms and plasticity, which drive onset, progression, therapeutic response and resistance in melanoma. Going forward, elucidation of noncoding RNA-mediated mechanisms may provide insights that accelerate development of novel melanoma therapies.

AB - Melanoma, the cancer of the melanocyte, is the deadliest form of skin cancer with an aggressive nature, propensity to metastasize and tendency to resist therapeutic intervention. Studies have identified that the re-emergence of developmental pathways in melanoma contributes to melanoma onset, plasticity, and therapeutic response. Notably, it is well known that noncoding RNAs play a critical role in the development and stress response of tissues. In this review, we focus on the noncoding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and other small RNAs, for their functions in developmental mechanisms and plasticity, which drive onset, progression, therapeutic response and resistance in melanoma. Going forward, elucidation of noncoding RNA-mediated mechanisms may provide insights that accelerate development of novel melanoma therapies.

KW - Humans

KW - RNA, Untranslated/genetics

KW - MicroRNAs/genetics

KW - Melanoma/drug therapy

KW - RNA, Long Noncoding/genetics

KW - RNA, Circular

U2 - 10.1016/j.pharmthera.2023.108466

DO - 10.1016/j.pharmthera.2023.108466

M3 - Review article

C2 - 37301330

SN - 0163-7258

VL - 248

SP - 108466

JO - Pharmacology & therapeutics

JF - Pharmacology & therapeutics

ER -

Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this